Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Nexalin Technology, Inc. - Common Stock (NQ: NXL ) 1.640 +0.540 (+49.09%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 57,581,151 Open 1.100 Bid (Size) 2.300 (44) Ask (Size) 2.310 (11) Prev. Close 1.100 Today's Range 1.030 - 2.720 52wk Range 0.2528 - 3.400 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Why Kaival Brands Innovations Shares Are Trading Lower By 47%? Here Are Other Stocks Moving In Friday's Mid-Day Session June 21, 2024 Via Benzinga Why Are Nexalin Technology Shares Surging Friday? June 21, 2024 Nexalin Technology, Inc. (NASDAQ: NXL) shares surged on Friday afternoon following the announcement of a new patent awarded by the United States Patent and Trademark Office (USPTO). Via Benzinga Topics Intellectual Property Exposures Intellectual Property Performance YTD +311.75% +311.75% 1 Month +42.61% +42.61% 3 Month +238.84% +238.84% 6 Month +355.94% +355.94% 1 Year +92.49% +92.49% More News Read More Nano-Cap Nexalin Technology Secures US Patent For Stimulation Device For Alzheimer's And Dementia Treatment June 20, 2024 Via Benzinga Topics Intellectual Property Exposures Intellectual Property Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session June 20, 2024 Via Benzinga Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia June 20, 2024 From Nexalin Technology, Inc. Via GlobeNewswire Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket June 20, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday June 20, 2024 Via InvestorPlace 12 Health Care Stocks Moving In Wednesday's After-Market Session June 19, 2024 Via Benzinga 12 Health Care Stocks Moving In Wednesday's Intraday Session June 19, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's After-Market Session June 18, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's After-Market Session June 17, 2024 Via Benzinga 12 Health Care Stocks Moving In Friday's After-Market Session June 14, 2024 Via Benzinga Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session June 14, 2024 Via Benzinga 12 Health Care Stocks Moving In Friday's Intraday Session June 14, 2024 Via Benzinga Dow Tumbles Over 200 Points; Adobe Earnings Top Views June 14, 2024 Via Benzinga Topics Stocks Exposures US Equities Why Is Gain Therapeutics (GANX) Stock Down 25% Today? June 14, 2024 Via InvestorPlace Why Is Nexalin Technology (NXL) Stock Down 29% Today? June 14, 2024 Via InvestorPlace Why Adobe Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket June 14, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday June 14, 2024 Via InvestorPlace Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV June 14, 2024 Via ACCESSWIRE 12 Health Care Stocks Moving In Thursday's After-Market Session June 13, 2024 Via Benzinga Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa) June 13, 2024 From Nexalin Technology, Inc. Via GlobeNewswire MicroCap Rodeo’s Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies June 06, 2024 Via ACCESSWIRE Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th June 04, 2024 From Nexalin Technology, Inc. Via GlobeNewswire FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device June 03, 2024 From Nexalin Technology, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
